RUSH: Mesa, Arizona, speaking of which, here’s John. You’re next on the EIB Network, John. Thank you for waiting. Great to have you on the program.

CALLER: Hey, Rush. How you doing?

RUSH: Fine, sir. Thank you.

CALLER: Hey, I was listening a long time ago to your show. I found out that you’d been doing a lot of fundraising for blood cancer research, and ever since then I’ve been trying to call in and actually thank you because I have multiple myeloma. I was diagnosed two and a half years ago, and treatment has gone fantastic. At the time I was diagnosed, my myeloma cells were 70% in my marrow, and now it’s down to 1%.

RUSH: Holy… That is excellent.

CALLER: Yeah, and next month I’m gonna be doing the stem cell transplant, which my oncologist and the transplant specialist are very confident is gonna put me in remission.

RUSH: That would not have been possible all that long ago.

CALLER: No.

RUSH: There’s been a tremendous amount of progress and research and all that made in exactly that kind of —

CALLER: That’s what I was gonna say. That’s what I was gonna say, too, is the drug I’m on was FDA approved in 2003, and it has since become the primary treatment for multiple myeloma and it’s just doing fantastic work not only for me but for other people as well, it’s just doing fantastic, you know. So I just wanted to call you and thank you for your part in that.

RUSH: Ah, don’t thank me. Thank the audience. This audience has come through with almost 35 or $40 million over the years, it’s incredible. It started somewhat small, but it keeps building and building every year. But that’s great. Everybody appreciates that, but more than that we’re happy that this is all working for you. That’s just tremendous. I’m glad that you called, John. Thank you much.